The JAK/STAT signaling pathway plays a key role in cancer development, immunity, tumorigenesis, chemotherapy resistance, and metastatic capacity [38,39], and it is associated with poor clinical outcomes when activated [40]. This evidence concerns the gene SOAT1 and cancer.